Agenus Inc. Free Cash Flow Margin

Free Cash Flow Margin of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2019 was -15.55% (a -95.75% decrease from previous year)
  • Annual Free Cash Flow Margin for 2018 was -366.15% (a 61.47% increase from previous year)
  • Annual Free Cash Flow Margin for 2017 was -226.76% (a -44.65% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending June 29, 2020 was -139.98% (a -10.62% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin increased by 534.54% year-over-year
Trailing Free Cash Flow Margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-139.98% -156.62% -15.55% -22.06%
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of Agenus Inc.

Most recent Free Cash Flow Marginof AGEN including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of Agenus Inc.

Agenus Inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -15.55%
2018 -366.15%
2017 -226.76%
2016 -409.69%
2015 -204.56%
2014 -588.38%
2013 -668.15%
2012 5.7%
2011 -590.74%
2010 -441.66%
2009 -731.26%

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.